Alpha-fetoprotein–producing recurrent nasopharyngeal carcinoma: A case report

Zhen-Chong Yang1,2*, Mei-Juan Luo1,2*, Li-Li Liu1,3*, Mu-Yan Cai1,3*, Yu-Jing Liang1,2, Qiu-Yan Chen1,2, Lin-Quan Tang1,2 and Hai-Qiang Mai1,2

Abstract

Alpha-fetoprotein hardly increased due to nasopharyngeal cancer. In this article, we reported a 57-year-old male nasopharyngeal carcinoma patient who had posttreatment subscapular metastasis with high serum alpha-fetoprotein but negative plasma Epstein–Barr virus DNA. Pathology results indicated that the scapular mass was undifferentiated non-keratinizing carcinoma originated in the nasopharynx. Moreover, no liver lesion was detected by imaging examination. In view of the positive alpha-fetoprotein and alpha-fetoprotein messenger RNA staining result in the right scapular mass fine needle aspiration biopsy sample, we considered the diagnosis of alpha-fetoprotein-producing nasopharyngeal carcinoma that had never been reported before.

Keywords

Nasopharyngeal carcinoma, alpha-fetoprotein, bone metastasis

Date received: 5 July 2021; accepted: 14 October 2021

Background

Nasopharyngeal carcinoma (NPC) is an epidemic in Southern China and the surrounding regions.1 Plasma Epstein–Barr virus (EBV) DNA is widely used as a biomarker for NPC.2 Alpha-fetoprotein (AFP) is a protein produced in the liver of a developing fetus and used as a tumor marker to help detect and diagnose cancers of the liver, testicles, and ovaries.3 Previous study considered AFP nearly useless in NPC patients since NPC did not produce AFP.4 However, we found a pathology-confirmed AFP-producing NPC patient with high serum AFP. Serum level of AFP decreased with the shrinking of tumor size and increased along with tumor progression. In this case, dynamic changes in AFP levels could predict treatment response instead of EBV infection status. We recorded this rare phenomenon and present our experience in diagnosing AFP-producing NPC.

Case presentation

In June 2019, a 57-year-old Cantonese male patient presented with a mass in the right subscapular area. His past medical history included a diagnosis of undifferentiated non-keratinizing NPC (World Health Organization type III, restaged as T3N1M0 III according to the American Joint Committee on Cancer staging manual, 8th edition) 18 months prior to the present episode of care. At that time, the pathological diagnosis was based on

1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
2Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China
3Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China
4Zhen-Chong Yang, Mei-Juan Luo, Li-Li Liu and Mu-Yan Cai have contributed equally to this work.

Corresponding Authors:

Lin-Quan Tang, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. Email: tanglq@sysucc.org.cn

Hai-Qiang Mai, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. Email: maihq@mail.sysu.edu.cn
These results, we initiated the diagnostic assessment. Found no lesions in the liver or signs of a tumor. Considering was unclear. PET/CT and abdomen ultrasonography imaging between the inferior scapular muscle and supraspinal muscle soft tissue shadows in the scapular lesion, and the boundary the maximum standardized uptake value of 8.0. We observed right scapula (Figure 1). This was considered a metastasis with PET/CT scanning indicated bone destruction in the liver showed no tumor site (Figure S1). Concurrent chemotherapy regimen comprised 100 mg/m² of cisplatin for three cycles. The patient experienced no serious adverse events during treatment and achieved complete response. After 1 year of follow-up, he remained without signs of disease progression. Three months prior to the present episode of care, the patient felt tightness in the right scapula and discovered an enlarged mass.

On the day of admission, the patient had a major complaint of paroxysmal scapula pain without other symptoms. He experienced rapid weight loss (3 kg in the month prior to admission). The patient never drank alcohol or smoked and indicated no family history of cancer, autoimmune disorders, and infectious diseases. On physical examination, his temperature was 36.6°C, heart rate was 79 beats per minute, blood pressure was 109/76 mmHg, weight was 50.3 kg, and height was 166 cm. We found no visible mass in the nasopharynx or enlarged cervical lymph nodes. The scapular mass measured 4 cm × 8 cm. His neurological examination was normal. Laboratory findings on admission are shown in Table 1. Notably, serum AFP level was 20,886 ng/mL (reference range: 0–25 ng/mL), but liver transaminases were normal. Plasma EBV DNA remained negative.

Subsequent positron emission tomography–computed tomography (PET/CT) scanning indicated bone destruction in right scapula (Figure 1). This was considered a metastasis with the maximum standardized uptake value of 8.0. We observed soft tissue shadows in the scapular lesion, and the boundary between the inferior scapular muscle and supraspinal muscle was unclear. PET/CT and abdomen ultrasonography imaging found no lesions in the liver or signs of a tumor. Considering these results, we initiated the diagnostic assessment.

**Differential diagnosis**

**Viral hepatitis.** In China, viral hepatitis infections incur a high burden with an annual incidence of hepatitis B of 81.57 per 100,000 persons, the second highest rate among all infectious diseases. Patients with viral hepatitis or cirrhosis may have increased levels of serum AFP, although this change is brief and small in magnitude. Viral hepatitis infection is diagnosed based on a patient’s epidemiological history, clinical symptoms, and laboratory tests.

In our case, the patient indicated no history of viral hepatitis infection and had no clinical symptoms or elevated transaminase levels. Serum biochemical examination revealed no evidence of hepatic dysfunction or hepatitis B or C. Moreover, the patient tested negative for antibodies of hepatitis A, C, and E. Regarding hepatitis B, the patient also tested negative for the hepatitis B surface antigen, hepatitis Be antigen (HBeAg), and antibody to HBeAg (anti-HBe) (Table 1). Furthermore, hepatitis B virus DNA copy number was 0 IU/mL. Thus, the significant increase in AFP levels was not related to a viral hepatitis infection.

**Hepatocellular carcinoma.** Hepatocellular carcinoma (HCC) is mostly detected in chronic liver disease cases that have reached the stage of cirrhosis. Chronic infection with hepatitis B or C viruses and excessive alcohol consumption are the most common causes of HCC worldwide. Abdomen ultrasonography, CT, and magnetic resonance imaging (MRI) are imaging surveillance tools for HCC detection.

AFP levels were commonly used as a serum marker for auxiliary diagnosis of HCC; thus, the sharp increase in AFP levels of our patient indicated a possible HCC diagnosis. However, we found no evidence of liver lesions, viral hepatitis infection, and/or cirrhosis. The results of the abdomen ultrasonography and PET/CT imaging did not support the existence of tumors in the liver. Therefore, we should carefully consider the amplitude and dynamic changes in AFP levels and its relationship with transaminase levels, as well as combine clinical manifestations with liver imaging examination findings.

**Liver metastasis from NPC.** The patient had a history of NPC with complete response after chemoradiotherapy and discharge over 1 year ago. In the follow-up evaluation, PET/CT scan showed bone metastases without liver metastasis. Furthermore, the significant increase in serum AFP level and negative EBV infection status were inconsistent with the clinical manifestation of NPC liver metastases. Dynamic measurements of serum EBV DNA and AFP levels, as well as other imaging examinations, were evaluated repeatedly. Contrast-enhanced ultrasonography and MRI examinations of the liver showed no tumor site (Figure S1).

**Histopathological examination.** Fine needle aspiration (FNA) biopsy of the scapular mass revealed poorly differentiated cancer cells varying in size and shape. Immunohistochemistry examination indicated that the tumor was positive for pan cytokeratin (AE1/AE3) and negative for LCA, HepPar1, and glypican-3 (Figure 2(m)–(t)). The tumor had a focal and patchy staining for AFP.

RNA scope method represents a significant advancement that addresses the challenges of traditional RNA in situ hybridization while providing spatial and morphological resolution at a single-cell level. Thus, we used the RNA scope method, which also showed positive for AFP by in situ hybridization. Moreover, the tumor cells were negative for EBV-encoded small RNA (EBER) by in situ hybridization. Positive staining for CK, Ki67, and P63 indicated that the tumor originated in the squamous epithelium, most likely in the nasopharynx considering the patient’s medical history.

The negative result for EBER was unusual for NPC metastasis. Hence, we reassessed the nasopharynx biopsy performed...
| Variable                              | Reference rangea | 18 months before current admission | On admission | After two cycles of chemotherapy | After four cycles of chemotherapy |
|---------------------------------------|------------------|-----------------------------------|--------------|----------------------------------|----------------------------------|
| Hemoglobin (g/L)                      | 130.0–175.0      | 153.0                             | 144.0        | 106.0                            | 95.0                             |
| Hematocrit (%)                        | 40.0–50.0        | 47.1                              | 44.6         | 31.9                             | 28.7                             |
| White cell count (10^9/L)             | 3.5–9.5          | 6.01                              | 7.23         | 3.79                             | 2.82                             |
| Differential count (%)                |                  |                                   |              |                                  |                                  |
| Neutrophils                           | 40–75            | 63.5                              | 74.8         | 80.2                             | 71.6                             |
| Lymphocytes                           | 20–50            | 25.3                              | 12.4         | 12.1                             | 23.4                             |
| Monocytes                             | 3–10             | 8.0                               | 10.7         | 6.6                              | 3.9                              |
| Eosinophils                           | 0.4–8.0          | 2.5                               | 1.8          | 0.8                              | 0.4                              |
| Basophils                             | 0–1              | 0.7                               | 0.3          | 0.3                              | 0.7                              |
| Platelet count (10^9/L)               | 100.0–300.0      | 209.0                             | 202.0        | 130.0                            | 255.0                            |
| Sodium (mmol/L)                       | 137–147          | 140.3                             | 139.3        | 140.8                            | 136.0                            |
| Potassium (mmol/L)                    | 3.5–5.3          | 4.51                              | 4.31         | 4.52                             | 4.69                             |
| Chloride (mmol/L)                     | 99–101           | 104.6                             | 103.2        | 103.7                            | 99.5                             |
| Carbon dioxide (mmol/L)               | 23–29            | 22.1                              | 24.0         | 23.1                             | 23.0                             |
| Urea (mmol/L)                         | 3.1–8.0          | 6.8                               | 7.1          | 6.8                              | 7.8                              |
| Creatinine (μmol/L)                   | 57–97            | 99.3                              | 99.7         | 97.5                             | 102.8                            |
| Glucose (mmol/L)                      | 3.9–6.1          | 4.93                              | 10.90        | 5.29                             | 5.05                             |
| Calcium (mmol/L)                      | 2.11–2.52        | 2.18                              | 2.34         | 2.10                             | 2.18                             |
| Total protein (g/L)                   | 65–85            | 71.29                             | 72.16        | 67.20                            | 78.06                            |
| Albumin (g/L)                         | 40–55            | 45.1                              | 43.9         | 40.1                             | 47.0                             |
| Alanine aminotransferase (U/L)        | 9–50             | 13.8                              | 8.5          | 16.4                             | 10.8                             |
| Aspartate aminotransferase (U/L)      | 15–40            | 20.6                              | 17.3         | 18.7                             | 37.0                             |
| Alkaline phosphatase (U/L)            | 40–150           | 54.0                              | 68.7         | 56.8                             | 43.1                             |
| Total bilirubin (μmol/L)              | 5–20.5           | 17.8                              | 9.4          | 7.6                              | 15.8                             |
| C-reactive protein (mg/L)             | 0–3.0            | 6.21                              | 2.71         | 2.51                             | 3.07                             |
| Prothrombin time (s)                  | 10.5–13.5        | 10.6                              | 12.4         | 12.1                             | 13.0                             |
| Prothrombin activity (%)              | 70.0–130.0       | 118.6                             | 92.0         | 92.5                             | 78.4                             |
| International normalized ratio        | 0.85–1.20        | 0.92                              | 1.08         | 1.06                             | 1.14                             |
| Partial thromboplastin time (s)       | 22.5–34.0        | 19.3                              | 20.6         | 23.6                             | 25.9                             |
| Fibrinogen (g/L)                      | 1.80–4.00        | 2.21                              | 4.15         | 3.58                             | 2.86                             |
| Thrombin time (s)                     | 14.0–21.0        | 18.5                              | 16.2         | 17.8                             | 17.5                             |
| D-dimer (μg/mL)                       | 0.00–0.55        | 0.11                              | 0.87         | 28.53                            | 0.90                             |
| Fibrinogen degradation products (μg/mL)| 0.0–5.0          | 0.7                               | 3.6          | 87.6                             | 4.0                              |
| EBV DNA (copy/mL)                     | < 1000           | 0                                 | 0            | 0                                | 0                                |
| Alpha-fetoprotein (ng/mL)             | 0.00–25.00       | ND                                | 20.886       | 20.015                           | 5455                            |
| HBV DNA (IU/mL)                       | < 100            | ND                                | 0            | 0                                | 0                                |
| HBsAg (COI)                           | 0–0.999          | 0.00 IU/mL                        | 0.215 (−)    | ND                               | Negative (−)                     |
| HBsAb (IU/L)                          | 0–9.999          | ND                                | 115.0 (+)    | ND                               | Positive (+)                     |
| HBeAg (COI)                           | 0–0.999          | ND                                | 0.099 (−)    | ND                               | Negative (−)                     |
| HBeAb (COI)                           | 0.999–9.999      | ND                                | 1.27 (−)     | ND                               | Negative (−)                     |
| HBcAb (COI)                           | 0.999–9.999      | ND                                | 0.027 (+)    | ND                               | Positive (+)                     |
| Anti-HCV (S/CO)                       | 0–0.999          | 0.06                              | 0.07         | ND                               | 0.14                             |
| HIV-Ab (COI)                          | 0–0.999          | 0.09 COI                          | 0.175/CO     | ND                               | 0.145/CO                        |
| Anti-TP (S/CO)                        | 0–0.999          | 0.04                              | 0.13         | ND                               | 0.07                             |
| VCA-IgA                                | Negative (−)     | 1:10                              | ND           | ND                               | ND                               |
| EA-IgA                                 | Negative (−)     | Negative (−)                      | ND           | ND                               | ND                               |
| EBNA1-IgA                              | Negative (−)     | Negative (−)                      | ND           | ND                               | ND                               |
| Zta-IgA                                | Negative (−)     | Negative (−)                      | ND           | ND                               | ND                               |
| Rta-IgG                                | Negative (−)     | Negative (−)                      | ND           | ND                               | ND                               |

EBV: Epstein–Barr virus; DNA: deoxyribonucleic acid; ND: not done; HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; HBsAb: hepatitis B surface antibody; HBeAg: hepatitis Be antigen; HBeAb: hepatitis B core antibody; HbcAb: hepatitis B core antibody; HCV: hepatitis C virus; HIV-Ab: human immunodeficiency virus antibody; TP: treponema pallidium; VCA-IgA: viral capsid antibody; EA-IgA: early antigen antibody; EBNA1-IgA: Epstein–Barr virus nuclear antigen 1; Zta-IgA: Zta protein antibody; Rta-IgA: Rta protein antibody.

*Reference ranges used at the Sun Yat-sen University Cancer Center and may not be appropriate for all patients.
before the chemoradiotherapy. The biopsy sample was taken from the left pharyngeal recess and diagnosed as undifferentiated non-keratinizing carcinoma by microscopic examination. We observed microscopically large tumor cells with a syncytial appearance, round to oval vesicular nuclei, and large central nucleoli. Malignant cells assumed spindle-cell features in fascicular arrangements. Immunohistochemistry and in situ hybridization assays were performed to determine whether the scapular mass originated in the pharynx. Table 2 summarized the comparison of the primary and metastatic tumor site.
Immunohistochemistry assay results indicated that the tumor was positive for pan cytokeratin (AE1/AE3), CK5/6, p40, CAM5.2, EMA, and INI; and negative for Syn, CgA, CD56, MPO, CD20, CD3, CD 43, HMB 45, Melan-A, and S-100 (Figure 2(a)–(l)). Tumor cells were negative for EBER by in situ hybridization. The positive staining for CK, p40, CAM5.2, and EMA indicated a diagnosis of undifferentiated non-keratinous carcinoma. Other tumors—including lymphoma, melanoma, olfactory neuroblastoma, high-grade neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma—were ruled out.

NPCs are histologically classified into the following four subtypes based on morphologic characteristics: epithelial carcinoma (EC), sarcomatoid carcinoma (SC), mixed...
sarcomatoid-epithelial carcinoma (MSEC), and squamous cell carcinoma (SCC).\textsuperscript{12,13} Our case is EC subtype, most of the tumor regions are identified with round epithelial cells and vesicular nuclei phenotype appearance. Figure 2(a) and (m) represent histological view of the primary and recurrent tumors, which shows similar morphologic traits. EC subtype is more responsive to EGFR inhibitors, which is synergistically enhanced by combining with radiotherapy. Moreover, radiochemotherapy significantly improved survival compared with radiotherapy alone for patients with EC subtype.

Compared with the scapular mass, all the immunohistochemistry results were similar in the nasopharynx biopsy, except that AFP was not detected in the primary nasopharynx biopsy (Table 2). The above results indicated that the scapular mass originated in the nasopharynx. Additional immunohistochemistry analysis for HepParl, glypican-3, and AFP, was obtained, obtaining negative results. Nonetheless, high serum AFP levels still represented an unusual presentation in NPC. In view of the positive AFP staining result in the right scapular mass FNA biopsy sample, we considered the diagnosis of AFP-producing NPC.

**Gene sequencing.** The FNA biopsy sample of the right scapular mass was used for next-generation sequencing testing. Microsatellite-stability status was determined, and the tumor mutational burden was low (1 Muts/Mb) with no detectable genomic alterations. Variants of unknown significance (VUS) of FGFR3, GNAS, and ZNF217 (Table S1) were identified in the FNA biopsy sample, but they remain insufficiently investigated.

The human FGFR3 gene (located on 4p16.3) provides instructions for encoding a protein called fibroblast growth factor receptor 3. FGFR3 mutations are associated with several diseases, including achondroplasia. \textsuperscript{14} FGFR3-TACC3 fusions were found in gliomas, urothelial cancer, non-small cell lung cancer, and other solid tumors.\textsuperscript{14} Over-expression of FGFR3 may play an important role in liver carcinogenesis. FGFR3 may be an ideal candidate as a molecular marker in the diagnosis of HCC and a potential therapeutic target.\textsuperscript{15,16} Moreover, FGFR4 contributes significantly to HCC progression by modulating AFP secretion.\textsuperscript{16} That is, the AFP-producing process might be induced by the FGFR3 mutations. The GNAS gene (located on 20q13.32) codes for the G protein Ga. GNAS mutations are associated with human thyroid and pituitary tumors.\textsuperscript{17} However, our patient exhibited p.Gly44Ser and G215D amino acid changes, which are rarely reported as missense VUS.\textsuperscript{18} Finally, ZNF217 (located on 20q13.2) is a marker of poor prognosis in breast cancer and glioma.\textsuperscript{19} The mutation of the base corresponding to the 667th amino acid encoding the ZNF217 protein causes a change in the mRNA codon, leading to premature stop codon and subsequently resulting in early termination of protein production and loss of protein function. However,
the clinical significance of this mutation is unclear. Previous studies reported that GNAS and ZNF217 are associated with HCC progression,20,21 and we believed these mutations were the cause of the unusual AFP production in NPC.

Discussion

Adults with elevated serum AFP levels require differential diagnosis for malignant diseases, such as liver cancer, germ cell tumors (e.g. yolk sac tumor), and metastatic lung cancer—and benign diseases, such as acute or chronic hepatitis, liver cirrhosis, and congenital biliary atresia.3 Considering the results of pathological examinations, our patient received a final diagnosis of AFP-producing NPC with multiple metastases. AFP is mainly synthesized by fetal liver cells and yolk sac, the prognostic role of which in NPC remains unclear. AFP-producing malignancies of the ovaries or gastrointestinal tract were with a poor prognosis.22,23 In this case, FGFR3, GNAS, and ZNF217 mutations might be the reason for the AFP-producing process and provide a hint for the potential therapeutic target. Chen et al.24 reported that EBER-positive signals were detected in 91.43% patients with non-keratinizing NPC in China. Those patients with negative EBER are considered to have poorer clinical outcomes compared to EBER-positive NPC.25 Therefore, this AFP-positive and EBER-negative patient might not have favorable clinical outcome and no definite therapy is available for this type of cancer. We deemed molecular targeted therapy or immunotherapy likely to be ineffective.

A multicenter, phase III, randomized clinical trial provided evidence that gemcitabine plus cisplatin is superior to 5-fluorouracil plus cisplatin in metastatic NPC treatment.26 Because the patient’s plasma creatinine level was less than 60 mL/(min×1.73 m²), we replaced cisplatin for capecitabine in his treatment regimen. He received two cycles of chemotherapy with gemcitabine 1000 mg/m² on days 1 and 8 every 3 weeks, and capecitabine 1500 mg/m² on days 1–14 every 3 weeks. During chemotherapy, he had clinical symptoms and reported dental ulcer, odynophagia, and weight loss. After chemotherapy regimen completion, the scapular mass volume slightly decreased but the patient’s scapular pain persisted and he developed a new axillary lymph node metastasis (Figure 1(c)). Therefore, we confirmed disease progression after first-line chemotherapy. Moreover, serum AFP levels remained elevated and serum EBV DNA was still negative.

Few studies have evaluated the efficacy of chemotherapy as a second-line treatment for metachronous metastasis of NPC patients. We used albumin-bound paclitaxel 100 mg/m² every week and apatinib 500 mg once a day for two cycles (1 cycle = 3 weeks). The patient reported relief of symptoms after second-line treatment and the tumor mass and volume reduced significantly. Post-treatment MRI scan did not detect liver lesions and serum AFP level decreased from 20,886 ng/mL to approximately 5000 ng/mL. High serum AFP levels may be explained by the presence of AFP-producing NPC, as indicated by pathological examination. The patient underwent second-line treatment regimen maintenance and remained symptom-free with a stable disease and improved quality of life for 6 months. In March 2020, the right scapular mass increased again, accompanied by an increase in plasma AFP levels (Figure 1(e)). The patient refused further chemotherapy and died surrounded by his family 4 months later.

Final diagnosis

AFP-producing EBV-negative metastatic NPC, which had never been reported before. In addition, this type of NPC is with poor prognosis.

Conclusion

AFP-producing EBV-negative metastatic NPC had poor treatment response to the regular chemotherapy of NPC. In this case, FGFR3, GNAS, and ZNF217 mutations might be the reason for the AFP-producing process and provide a hint for the potential therapeutic target.

Acknowledgements

We would like to thank the NPC patient and his family for allowing us to publish this unique case.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

This study had institution ethical approval for reporting this individual case.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent

Written informed consent was obtained from a legally authorized representative(s) for anonymized patient information to be published in this article.

ORCID iD

Hai-Qiang Mai https://orcid.org/0000-0003-0214-203X

Supplemental material

Supplemental material for this article is available online.

References

1. Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma. Lancet 2019; 394: 64–80.
2. Chen WJ, Xu WN, Wang HY, et al. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population. BMC Cancer 2021; 21: 651.
3. Shaib W, Sharma R, Mosunjac M, et al. Hepatoid adenocarcinoma of the lung: a case report and review of the literature. *J Gastrointest Cancer* 2014; 45(Suppl. 1): 99–102.

4. Kuo WR, Tsai SM, Jong SB, et al. Significance of tumour markers in nasopharyngeal carcinoma. *J Otolaryngol* 1996; 25(1): 32–36.

5. Yang S, Wu J, Ding C, et al. Epidemiological features of and changes in incidence of infectious diseases in China in the first decade after the SARS outbreak: an observational trend study. *Lancet Infect Dis* 2017; 17(7): 716–725.

6. Sauzay C, Petit A, Bourgeois AM, et al. Alpha-foetoprotein (AFP): a multi-purpose marker in hepatocellular carcinoma. *Clin Chim Acta* 2016; 463: 39–44.

7. McGlynn KA, Petrick JL and El-Serag HB. Epidemiology of hepatocellular carcinoma. *Hepatology* 2021; 73: 4–13.

8. Wong RJ, Ahmed A and Gish RG. Elevated alpha-fetoprotein: differential diagnosis—hepatocellular carcinoma and other disorders. *Clin Liver Dis* 2015; 19(2): 309–323.

9. Singal AG, Lampertico P and Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. *J Hepatol* 2020; 72(2): 250–261.

10. Anderson CM, Zhang B, Miller M, et al. Fully automated RNAscope in situ hybridization assays for formalin-fixed paraffin-embedded cells and tissues. *J Cell Biochem* 2016; 117(10): 2201–2208.

11. Pellegrini G, Dellambra E, Golisano O, et al. p63 identifies keratinocyte stem cells. *Proc Natl Acad Sci USA* 2001; 98: 3156–3161.

12. Wang HY, Chang YL, To KF, et al. A new prognostic histopathologic classification of nasopharyngeal carcinoma. *Chin J Cancer* 2016; 35: 41.

13. Ding R-B, Chen P, Rajendran BK, et al. Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics. *Nat Commun* 2021; 12: 3046.

14. Costa R, Carneiro BA, Taxter T, et al. FGFR3-TACC3 fusion in solid tumors: mini review. *Oncotarget* 2016; 7: 55924–55938.

15. Qiu WH, Zhou BS, Chu PG, et al. Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. *World J Gastroenterol* 2005; 11: 5266–5272.

16. Ho HK, Pok S, Streit S, et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. *J Hepatol* 2009; 50(1): 118–127.

17. O’Hayre M, Vazquez-Prado J, Kufareva I, et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. *Nat Rev Cancer* 2013; 13(6): 412–424.

18. Tezcan G, Tunca B, Ak S, et al. Molecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancer. *World J Gastrointest Oncol* 2016; 8: 83–98.

19. Vendrell JA, Thollet A, Nguyen NT, et al. ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion. *Cancer Res* 2012; 72: 3593–3606.

20. Si W, Zhao Y, Zhou J, et al. The coordination between ZNF217 and LSD1 contributes to hepatocellular carcinoma progression and is negatively regulated by miR-101. *Exp Cell Res* 2019; 379: 1–10.

21. Ding H, Zhang X, Su Y, et al. GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation. *Cell Mol Biol Lett* 2020; 25: 8.

22. Iqbal J, Amir E, Rochon PA, et al. Association of the timing of pregnancy with survival in women with breast cancer. *JAMA Oncol* 2017; 3: 659–665.

23. Kafka M, Wöll E, Brunhuber T, et al. A presumed extragonadal germ cell tumor that turned out to be a gastric cancer—a case report. *Transl Androl Urol* 2021; 10(6): 2528–2533.

24. Chen HL, Peng J, Zhu XB, et al. Detection of EBV in nasopharyngeal carcinoma by quantum dot fluorescent in situ hybridization. *Exp Mol Pathol* 2010; 89(3): 367–371.

25. Zeng Z, Fan S, Zhang X, et al. Epstein-Barr virus-encoded small RNA 1 (EBER-1) could predict good prognosis in nasopharyngeal carcinoma. *Clin Transl Oncol* 2016; 18(2): 206–211.

26. Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. *Lancet* 2016; 388: 1883–1892.